Cambridge, United States
Spero Therapeutics, founded in 2013 and headquartered in the United States, is a multi-asset, clinical-stage biotech company specializing in treatments for multidrug-resistant bacterial infections and rare diseases. With a strong focus on addressing antibiotic resistance, the company is carving out a niche in an increasingly critical segment of the healthcare industry.
The company's lead candidate, SPR720, is an oral antimicrobial aimed at treating nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan illness. Through strategic partnerships, Spero is collaborating on SPR206, an intravenous option for MDR Gram-negative bacterial infections, and tebipenem HBr, intended as a pioneering broad-spectrum oral carbapenem-class antibiotic for complicated urinary tract infections.
Recent developments include receiving a $9.00M Post-IPO Equity investment from GlaxoSmithKline in September 2022, underscoring investor confidence in its potential to transform patient treatment options in hospitals and community settings.
